What Does This 2026 Review Say About CAR-T Therapy for Relapsed Multiple Myeloma?

If you are looking at CAR-T therapy for relapsed or refractory multiple myeloma, the first question is usually simple: is this a real option, or just another hopeful headline? The second question is harder: if it works for some people, how much uncertainty and risk comes with it?

This 2026 systematic review and meta-analysis looked at the published evidence on CAR-T therapy in people whose multiple myeloma had come back after treatment or had not responded well enough to earlier treatment ¹. It is encouraging, but it is not a promise of cure, and it should be read as a careful summary of early-to-mid clinical evidence rather than a guarantee for any one patient.

What question did the researchers ask?

Zhou and colleagues asked how effective and safe CAR-T therapy appears to be for people with relapsed or refractory multiple myeloma, often shortened to RRMM ¹. Multiple myeloma is a cancer of plasma cells, a type of immune cell found in the bone marrow. Relapsed means the disease returned after treatment; refractory means it did not respond adequately, or stopped responding.

The researchers searched PubMed, Web of Science, and Embase for studies published from 1 January 2021 to 1 August 2024. They identified 4,301 articles at first, then narrowed these down to 29 studies that met their inclusion criteria. In plain English, this was not a single hospital trial. It was a pooled review of many published studies, designed to ask: across the available literature, what pattern do we see?

CAR-T therapy is a form of immune-cell therapy in which a patient’s T cells are modified so they can better recognise a cancer target. If you are new to the idea, our overview of what CAR-T therapy is explains the basic concept without assuming a science background.

What did the review find?

The clearest number from the abstract is the overall response rate: 86%. That means that, across the included studies, about 86 out of 100 treated patients had a measurable response by the response definitions used in those studies.

That is a strong signal, especially in a relapsed or refractory setting. But response rate is not the same as permanent remission, cure, or being free from future treatment. The same abstract reported a median progression-free survival of 9.88 months and a median duration of response of 12.17 months. Median means half of patients did better than that point and half did worse; it does not predict an individual course.

The safety findings also matter. Cytokine release syndrome, or CRS, occurred in 83% of patients at any grade. Severe CRS, defined as grade 3 or higher, occurred in 5%. Severe neurotoxicity was reported in 2%, and infections were common, including severe infections in 21%.

How strong is this evidence?

A systematic review and meta-analysis can be helpful because it gathers many studies and looks for an overall pattern. That can make the signal clearer than reading one small trial in isolation. Here, the authors screened thousands of records and included 29 studies, which gives the paper more weight than a single-centre report.

But this type of evidence has limits. A meta-analysis is only as strong as the studies inside it. CAR-T studies in relapsed or refractory myeloma may differ in patient selection, prior treatments, CAR-T product, target, bridging therapy, follow-up time, and how side effects were measured. Combining those studies can estimate an average pattern, but it cannot erase the differences between them.

The abstract does not tell us every detail a treating haematologist would want to know: how many total patients were pooled, how many had high-risk disease, how many had kidney problems, how heavily pre-treated they were, or how results differed by CAR-T product. The paper is also not open access, so many patients will only see the abstract unless their physician or institution can access the full text.

The survival numbers should also be read cautiously. A median progression-free survival of 9.88 months suggests many patients still had disease progression within the first year. That does not make the treatment unimportant; in relapsed myeloma, gaining disease control can matter. But it does mean the evidence should not be framed as a simple cure story.

What could this mean if you are considering treatment?

For a prospective patient, the review supports a practical message: CAR-T therapy for relapsed or refractory multiple myeloma is a serious, evidence-based treatment area, not fringe medicine. It may produce meaningful responses in many treated patients, especially in specialist settings with experience in cell therapy.

At the same time, it is intensive care, not a wellness treatment. CAR-T can involve hospital monitoring, immune-related side effects, infection risk, and a recovery period that may affect travel plans. The decision is usually made with a haematologist or oncology team after reviewing disease stage, prior therapies, organ function, infection history, fitness for treatment, and available CAR-T products.

This review cannot tell you whether you personally are eligible, whether CAR-T is better than another next-line option for you, or whether travelling for treatment is wise. It can help you ask better questions: What CAR-T product is being discussed? What target does it use? How long would I need to stay near the treating centre? What happens if CRS, neurotoxicity, or infection develops? What is the plan after response or relapse?

What we see at the clinic

In Pattaya, our physicians are often asked whether CAR-T is “available,” but the deeper question is usually about suitability: whether a person’s diagnosis, prior treatment history, travel window, and support system make an advanced cell therapy pathway realistic. We also see that patients want plain explanations of risk, especially around fever-like immune reactions, infection monitoring, and how long they may need to remain close to specialist care.

Common questions

Is an 86% response rate the same as being cured? No. It means many patients had a measurable response in the pooled studies, but the review also reported a median progression-free survival of 9.88 months, so relapse or progression still occurred for many people.

Are the side effects usually mild? Not always. CRS was common at any grade, and severe infections were reported in 21% of patients, so this is a treatment that needs experienced monitoring rather than casual outpatient use.

Should I travel abroad for CAR-T therapy? That depends on eligibility, the treating centre, the CAR-T product, cost, timing, caregiver support, and what follow-up is available after you return home. This paper can inform the discussion, but it cannot replace advice from your oncology team.

[1] Zhou Y, Xie X, Feng K, Cao W, Zhang D. The efficacy and safety of CAR-T therapy in relapsed or refractory multiple myeloma patients: a systematic review and meta-analysis. Published 2026-01-08. https://doi.org/10.1080/16078454.2026.2613505

Key takeaway

This review suggests CAR-T therapy can produce high response rates in relapsed or refractory multiple myeloma, with one pooled estimate showing an 86% overall response rate. The same evidence also shows frequent side effects and limited durability for many patients, so the right expectation is careful hope, not certainty.